Sustained pre/Frailty | Robustness to pre/Frailty | pre/Frailty to robustness | Sustained robustness | |
---|---|---|---|---|
All-cause mortality | ||||
No. of participants (n) | 832 | 498 | 432 | 1043 |
Deaths (n) | 473 | 169 | 123 | 187 |
Follow-up (PYs) | 2388.9 | 1716.6 | 1553.1 | 3871.6 |
Mortality rate (95% CI)a | 19.8 (18.2-21.4) | 9.8 (8.4-11.3) | 7.9 (6.6-9.3) | 4.8 (4.2-5.5) |
Unadjusted HR (95% CI), p | 1.00 (ref) | 0.49 (0.41-0.58), <0.001 | 0.39 (0.32-0.48), <0.001 | 0.24 (0.20-0.28), <0.001 |
Adjusted HR (95% CI), p | ||||
model 1b | 1.00 (ref) | 0.57 (0.48-0.68), <0.001 | 0.50 (0.41-0.61), <0.001 | 0.37 (0.30-0.44), <0.001 |
model 2c | 1.00 (ref) | 0.61 (0.51-0.73), <0.001 | 0.51 (0.42-0.63), <0.001 | 0.41 (0.34-0.49), <0.001 |
E-valued | NA | 2.17 | 2.56 | 3.09 |
Cardiovascular death | ||||
No. of participants (n) | 832 | 498 | 432 | 1043 |
Deaths (n) | 75 | 36 | 18 | 41 |
Follow-up (PYs) | 2388.9 | 1716.6 | 1553.1 | 3871.6 |
Mortality rate (95% CI)a | 3.1 (2.4-3.8) | 2.1 (1.4-2.8) | 1.2 (0.6-1.7) | 1.1 (0.7-1.4) |
Unadjusted HR (95% CI), p | 1.00 (ref) | 0.65 (0.44-0.97), 0.037 | 0.36 (0.21-0.60), <0.001 | 0.33 (0.22-0.48), <0.001 |
Adjusted HR (95% CI), p | ||||
model 1b | 1.00 (ref) | 0.75 (0.50-1.12), 0.155 | 0.45 (0.26-0.75), 0.002 | 0.48 (0.32-0.72), <0.001 |
model 2c | 1.00 (ref) | 0.79 (0.52-1.19), 0.256 | 0.45 (0.26-0.76), 0.003 | 0.51 (0.33-0.78), 0.002 |
E-valued | NA | 1.86 | 3.87 | 3.33 |